These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12226743)

  • 1. A clinical protocol for treatment of canine mammary tumors using encapsulated, cytochrome P450 synthesizing cells activating cyclophosphamide: a phase I/II study.
    Winiarczyk S; Gradski Z; Kosztolich B; Gabler C; König G; Renner M; Saller RM; Prosl H; Salmons B; Günzburg WH; Hain J
    J Mol Med (Berl); 2002 Sep; 80(9):610-4. PubMed ID: 12226743
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.
    Michałowska M; Winiarczyk S; Adaszek Ł; Łopuszyński W; Grądzki Z; Salmons B; Günzburg WH
    PLoS One; 2014; 9(7):e102061. PubMed ID: 25028963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors.
    Müller P; Jesnowski R; Karle P; Renz R; Saller R; Stein H; Püschel K; von Rombs K; Nizze H; Liebe S; Wagner T; Günzburg WH; Salmons B; Löhr M
    Ann N Y Acad Sci; 1999 Jun; 880():337-51. PubMed ID: 10415878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy.
    Karle P; Müller P; Renz R; Jesnowski R; Saller R; von Rombs K; Nizze H; Liebe S; Günzburg WH; Salmons B; Löhr M
    Adv Exp Med Biol; 1998; 451():97-106. PubMed ID: 10026857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
    Jounaidi Y; Chen CS; Veal GJ; Waxman DJ
    Mol Cancer Ther; 2006 Mar; 5(3):541-55. PubMed ID: 16546968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
    Löhr M; Müller P; Karle P; Stange J; Mitzner S; Jesnowski R; Nizze H; Nebe B; Liebe S; Salmons B; Günzburg WH
    Gene Ther; 1998 Aug; 5(8):1070-8. PubMed ID: 10326030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
    Wei MX; Tamiya T; Rhee RJ; Breakefield XO; Chiocca EA
    Clin Cancer Res; 1995 Oct; 1(10):1171-7. PubMed ID: 9815909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
    Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of cyclophosphamide sensitivity in squamous cell carcinoma transfected with cytochrome P-450 2B1.
    Iida M; Kojima H; Miyazaki H; Manome Y
    Am J Otolaryngol; 2005; 26(1):22-7. PubMed ID: 15635577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
    Karle P; Renner M; Salmons B; Günzburg WH
    Cancer Gene Ther; 2001 Mar; 8(3):220-30. PubMed ID: 11332993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
    Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
    Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
    Kammertoens T; Gelbmann W; Karle P; Alton K; Saller R; Salmons B; Günzburg WH; Uckert W
    Cancer Gene Ther; 2000 Apr; 7(4):629-36. PubMed ID: 10811482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
    Tyminski E; Leroy S; Terada K; Finkelstein DM; Hyatt JL; Danks MK; Potter PM; Saeki Y; Chiocca EA
    Cancer Res; 2005 Aug; 65(15):6850-7. PubMed ID: 16061668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency and stability of compounded cyclophosphamide: a pilot study.
    Robat C; Budde J
    Vet Comp Oncol; 2017 Sep; 15(3):706-709. PubMed ID: 27028306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
    Ichikawa T; Petros WP; Ludeman SM; Fangmeier J; Hochberg FH; Colvin OM; Chiocca EA
    Cancer Res; 2001 Feb; 61(3):864-8. PubMed ID: 11221871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
    Günther M; Waxman DJ; Wagner E; Ogris M
    Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
    Jounaidi Y; Hecht JE; Waxman DJ
    Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
    Chen L; Yu LJ; Waxman DJ
    Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.